KALV vs. ABUS, ALIM, MGTA, BCRX, CPRX, ARVN, GLPG, KROS, NAMS, and HRMY
Should you be buying KalVista Pharmaceuticals stock or one of its competitors? The main competitors of KalVista Pharmaceuticals include Arbutus Biopharma (ABUS), Alimera Sciences (ALIM), Magenta Therapeutics (MGTA), BioCryst Pharmaceuticals (BCRX), Catalyst Pharmaceuticals (CPRX), Arvinas (ARVN), Galapagos (GLPG), Keros Therapeutics (KROS), NewAmsterdam Pharma (NAMS), and Harmony Biosciences (HRMY). These companies are all part of the "medical" sector.
KalVista Pharmaceuticals (NASDAQ:KALV) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment, analyst recommendations and community ranking.
In the previous week, Arbutus Biopharma had 10 more articles in the media than KalVista Pharmaceuticals. MarketBeat recorded 14 mentions for Arbutus Biopharma and 4 mentions for KalVista Pharmaceuticals. KalVista Pharmaceuticals' average media sentiment score of 0.47 beat Arbutus Biopharma's score of 0.28 indicating that KalVista Pharmaceuticals is being referred to more favorably in the media.
Arbutus Biopharma received 98 more outperform votes than KalVista Pharmaceuticals when rated by MarketBeat users. However, 73.93% of users gave KalVista Pharmaceuticals an outperform vote while only 70.93% of users gave Arbutus Biopharma an outperform vote.
Arbutus Biopharma has higher revenue and earnings than KalVista Pharmaceuticals. Arbutus Biopharma is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
KalVista Pharmaceuticals currently has a consensus target price of $25.00, suggesting a potential upside of 114.04%. Arbutus Biopharma has a consensus target price of $4.33, suggesting a potential upside of 35.42%. Given KalVista Pharmaceuticals' higher possible upside, research analysts plainly believe KalVista Pharmaceuticals is more favorable than Arbutus Biopharma.
43.8% of Arbutus Biopharma shares are held by institutional investors. 12.3% of KalVista Pharmaceuticals shares are held by company insiders. Comparatively, 4.0% of Arbutus Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
KalVista Pharmaceuticals has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. Comparatively, Arbutus Biopharma has a beta of 1.98, meaning that its share price is 98% more volatile than the S&P 500.
KalVista Pharmaceuticals has a net margin of 0.00% compared to Arbutus Biopharma's net margin of -572.81%. Arbutus Biopharma's return on equity of -62.68% beat KalVista Pharmaceuticals' return on equity.
Summary
Arbutus Biopharma beats KalVista Pharmaceuticals on 9 of the 15 factors compared between the two stocks.
Get KalVista Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KALV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
KalVista Pharmaceuticals Competitors List
Related Companies and Tools
